Company intelligence / Profile preview

Bright Cell, Inc.

Irvine, California, United Statesbrightcellgroup.com ↗

Ownership: Public · BHG
Development stage: Phase 2

Overview

Bright Cell, Inc. has two drug candidates in Phase 1 clinical trials: YB-1113 for Premature Ovarian Insufficiency and human umbilical cord tissue derived mesenchymal stem cells for nasolabial fold wrinkles. A Phase 1 study for YB-1113 is scheduled to start on January 9, 2025, to evaluate safety and tolerability via intravenous infusion.[2][6]

Therapeutic areas: Women's HealthDermatology
Modalities: Mesenchymal stem cell therapy
Industry: Biotech

Drug pipeline

2 assets

YB-1113

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $130.5M
Total revenue: $209.1M
Enterprise value: $-14.1M

Beyond the preview

Go deeper on Bright Cell, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bright Cell, Inc..

Explore the full profile